Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Zhi-Zhang Yang, Ai-Bin Liang & Stephen M. Ansell. (2015) T-cell-mediated antitumor immunity in B-cell non-Hodgkin lymphoma: activation, suppression and exhaustion. Leukemia & Lymphoma 56:9, pages 2498-2504.
Read now
Read now
Wataru Yamamoto, Naoya Nakamura, Naoto Tomita, Kengo Takeuchi, Yoshimi Ishii, Hiroyuki Takahashi, Reina Watanabe, Hirotaka Takasaki, Shigeki Motomura, Shoichi Kobayashi, Tomoyuki Yokose, Yoshiaki Ishigatsubo & Rika Sakai. (2014) Human leukocyte antigen-DR expression on flow cytometry and tumor-associated macrophages in diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy: retrospective cohort study. Leukemia & Lymphoma 55:12, pages 2721-2727.
Read now
Read now
Articles from other publishers (33)
Yu Zhang, Shuiyun Han, Xibing Xiao, Lu Zheng, Yingying Chen, Zhijian Zhang, Xinfang Gao, Shujuan Zhou, Kang Yu, Li Huang, Jiaping Fu, Yongwei Hong, Jinhong Jiang, Wenbin Qian, Haiyan Yang & Jianping Shen. (2023) Integration analysis of tumor metagenome and peripheral immunity data of diffuse large-B cell lymphoma. Frontiers in Immunology 14.
Crossref
Crossref
Rod Balhorn & Monique Cosman Balhorn. (2020) Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin’s lymphoma to many other types of solid cancers. Oncotarget 11:35, pages 3315-3349.
Crossref
Crossref
Xiaoguang Wang, Brittany C. Waschke, Rachel A Woolaver, Samantha M. Y. Chen, Zhangguo Chen & Jing H. Wang. (2020) HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma. Protein & Cell 11:7, pages 472-482.
Crossref
Crossref
Suet Ling Felce, Amanda P. Anderson, Shaun Maguire, Duncan M. Gascoyne, Richard N. Armstrong, Kah Keng Wong, Demin Li & Alison H. Banham. (2020) CRISPR/Cas9-Mediated Foxp1 Silencing Restores Immune Surveillance in an Immunocompetent A20 Lymphoma Model. Frontiers in Oncology 10.
Crossref
Crossref
Diego Villa, King L. Tan, Christian Steidl, Susana Ben-Neriah, Muntadhar Al Moosawi, Tamara N. Shenkier, Joseph M. ConnorsLaurie H. SehnKerry J. SavageDavid W. ScottRandy D. Gascoyne & Graham W. Slack. (2019) Molecular features of a large cohort of primary central nervous system lymphoma using tissue microarray. Blood Advances 3:23, pages 3953-3961.
Crossref
Crossref
Xiaoguang Wang, Brittany C. Waschke, Rachel A. Woolaver, Zhangguo Chen, Gan Zhang, Anthony D. Piscopio, Xuedong Liu & Jing H. Wang. (2019) Histone Deacetylase Inhibition Sensitizes PD1 Blockade–Resistant B-cell Lymphomas. Cancer Immunology Research 7:8, pages 1318-1331.
Crossref
Crossref
Mulder, Wahlin, Österborg & Palma. (2019) Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical Application. Cancers 11:7, pages 915.
Crossref
Crossref
Steven Dow & Amanda Guth. 2019. Withrow and MacEwen's Small Animal Clinical Oncology. Withrow and MacEwen's Small Animal Clinical Oncology
231
250
.
Melanie Grant & Catherine M. Bollard. (2017) Developing T-cell therapies for lymphoma without receptor engineering. Blood Advances 1:26, pages 2579-2590.
Crossref
Crossref
Melanie Grant & Catherine M. Bollard. (2017) Developing T-cell therapies for lymphoma without receptor engineering. Hematology 2017:1, pages 622-631.
Crossref
Crossref
Marie de Charette, Aurélien Marabelle & Roch Houot. (2016) Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?. European Journal of Cancer 68, pages 134-147.
Crossref
Crossref
Kohei Tada, Akiko Miyagi Maeshima, Nobuyoshi Hiraoka, Nobuhiko Yamauchi, Dai Maruyama, Sung-Won Kim, Takashi Watanabe, Naoyuki Katayama, Yuji Heike, Kensei Tobinai & Yukio Kobayashi. (2016) Prognostic significance of HLA class I and II expression in patients with diffuse large B cell lymphoma treated with standard chemoimmunotherapy. Cancer Immunology, Immunotherapy 65:10, pages 1213-1222.
Crossref
Crossref
Dorota Jesionek-Kupnicka, Marcin Bojo, Monika Prochorec-Sobieszek, Anna Szumera-Ciećkiewicz, Joanna Jabłońska, Ewa Kalinka-Warzocha, Radzisław Kordek, Wojciech Młynarski, Tadeusz Robak, Krzysztof Warzocha & Ewa Lech-Maranda. (2015) HLA-G and MHC Class II Protein Expression in Diffuse Large B-Cell Lymphoma. Archivum Immunologiae et Therapiae Experimentalis 64:3, pages 225-240.
Crossref
Crossref
P J Brown, K K Wong, S L Felce, L Lyne, H Spearman, E J Soilleux, L M Pedersen, M B Møller, T M Green, D M Gascoyne & A H Banham. (2015) FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas. Leukemia 30:3, pages 605-616.
Crossref
Crossref
Dammy Pinheiro, Yu-Mei Chang, Hannah Bryant, Balazs Szladovits, Tim Dalessandri, Lucy J. Davison, Elizabeth Yallop, Emily Mills, Chiara Leo, Ana Lara, Anneliese Stell, Gerry Polton & Oliver A. Garden. (2014) Dissecting the Regulatory Microenvironment of a Large Animal Model of Non-Hodgkin Lymphoma: Evidence of a Negative Prognostic Impact of FOXP3+ T Cells in Canine B Cell Lymphoma. PLoS ONE 9:8, pages e105027.
Crossref
Crossref
P.R. Avery, J. Burton, J.L. Bromberek, D.M. Seelig, R. Elmslie, S. Correa, E.J. Ehrhart, P.S. Morley & A.C. Avery. (2014) Flow Cytometric Characterization and Clinical Outcome of CD4+ T-Cell Lymphoma in Dogs: 67 Cases. Journal of Veterinary Internal Medicine 28:2, pages 538-546.
Crossref
Crossref
Kelly A. Cycon, Kathleen Mulvaney, Lisa M. Rimsza, Daniel Persky & Shawn P. Murphy. (2013) Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma. Immunology 140:2, pages 259-272.
Crossref
Crossref
Soham Puvvada, Samantha Kendrick & Lisa Rimsza. (2013) Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma. Cancer Genetics 206:7-8, pages 257-265.
Crossref
Crossref
Amanda M. Guth & Steven Dow. 2013. Withrow and MacEwen's Small Animal Clinical Oncology. Withrow and MacEwen's Small Animal Clinical Oncology
198
214
.
C. F. Skibola, N. K. Akers, L. Conde, M. Ladner, S. K. Hawbecker, F. Cohen, F. Ribas, H. A. Erlich, D. Goodridge, E. A. Trachtenberg, M. T. Smith & P. M. Bracci. (2012) Multi-locus HLA class I and II allele and haplotype associations with follicular lymphoma. Tissue Antigens 79:4, pages 279-286.
Crossref
Crossref
Sarah T. WilkinsonKristie A. Vanpatten, Diane R. FernandezPatrick BrunhoeberKarl E. Garsha, Betty J. Glinsmann-GibsonThomas M. Grogan, Julie Teruya-Feldstein & Lisa M. Rimsza. (2012) Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma. Blood 119:6, pages 1459-1467.
Crossref
Crossref
V. Procházka, M. Jarošová, Z. Prouzová, R. Nedomová, T. Papajík & K. Indrák. (2012) Immune Escape Mechanisms in Diffuse Large B-Cell Lymphoma. ISRN Immunology 2012, pages 1-6.
Crossref
Crossref
Christine F Skibola, Lucia Conde, Jia-Nee Foo, Jacques Riby, Keith Humphreys, Fenna CM Sillé, Hatef Darabi, Sylvia Sanchez, Henrik Hjalgrim, Jianjun Liu, Paige M Bracci & Karin E Smedby. (2012) A meta-analysis of genome-wide association studies of follicular lymphoma. BMC Genomics 13:1, pages 516.
Crossref
Crossref
Gaurav Malviya, E. F. J. de Vries, Rudi A. Dierckx & Alberto Signore. (2010) Synthesis and Evaluation of 99mTc-Labelled Monoclonal Antibody 1D09C3 for Molecular Imaging of Major Histocompatibility Complex Class II Protein Expression. Molecular Imaging and Biology 13:5, pages 930-939.
Crossref
Crossref
S. Rao, S. Lana, J. Eickhoff, E. Marcus, P.R. Avery, P.S. Morley & A.C. Avery. (2011) Class II Major Histocompatibility Complex Expression and Cell Size Independently Predict Survival in Canine B-Cell Lymphoma. Journal of Veterinary Internal Medicine 25:5, pages 1097-1105.
Crossref
Crossref
R.D. Gascoyne & C. Steidl. (2011) VII. The role of the microenvironment in lymphoid cancers. Annals of Oncology 22, pages iv47-iv50.
Crossref
Crossref
Kelly A. Cycon, James L. Clements, Renae Holtz, Hiroshi Fuji & Shawn P. Murphy. (2009) The immunogenicity of L1210 lymphoma clones correlates with their ability to function as antigen-presenting cells. Immunology 128:1pt2, pages e641-e651.
Crossref
Crossref
Kelly A. Cycon, Lisa M. Rimsza & Shawn P. Murphy. (2009) Alterations in CIITA constitute a common mechanism accounting for downregulation of MHC class II expression in diffuse large B-cell lymphoma (DLBCL). Experimental Hematology 37:2, pages 184-194.e2.
Crossref
Crossref
D. de Jong & G. Enblad. (2008) Inflammatory cells and immune microenvironment in malignant lymphoma. Journal of Internal Medicine 264:6, pages 528-536.
Crossref
Crossref
Lisa M. RimszaMichael L. LeBlancJoseph M. UngerThomas P. MillerThomas M. GroganDaniel O. PerskyRalph R. MartelConstantine M. SabalosBruce SeligmannRita M. BrazielElias CampoAndreas Rosenwald, Joseph M. Connors, Laurie H. Sehn, Nathalie Johnson & Randy D. Gascoyne. (2008) Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood 112:8, pages 3425-3433.
Crossref
Crossref
. (2007) Current Awareness in Hematological Oncology. Hematological Oncology 25:4, pages 204-211.
Crossref
Crossref
ELLEN LEICH, ELENA MARIA HARTMANN, CHRISTOF BUREK, GERMAN OTT & ANDREAS ROSENWALD. (2007) Diagnostic and prognostic significance of gene expression profiling in lymphomas. APMIS 115:10, pages 1135-1146.
Crossref
Crossref
Gaurav Malviya, Erik F.J. de Vries, Rudi A. Dierckx & Alberto Signore. (2007) Radiopharmaceuticals for imaging chronic lymphocytic inflammation. Brazilian Archives of Biology and Technology 50:spe, pages 1-13.
Crossref
Crossref